

Platinum Priority – Prostate Cancer
Editorial by Ian D. Davis on pp. 222–223 of this issue

Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial

Martin Bögemann^{a,*}, Neal D. Shore^b, Matthew R. Smith^c, Teuvo L.J. Tammela^d, Albertas Ulys^e, Egils Vjaters^f, Sergey Polyakov^g, Mindaugas Jievaltas^h, Murilo Luzⁱ, Boris Alekseev^j, Thierry Le Bret^k, Martin Schostak^l, Frank Verholen^m, Marie-Aude Le Berreⁿ, Shankar Srinivasan^o, Jorge Ortiz^o, Ateesha F. Mohamed^o, Toni Sarapohja^p, Karim Fizazi^q

^a Department of Urology, Münster University Medical Center, Münster, Germany; ^b Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA; ^c Massachusetts General Hospital Cancer Center, Boston, MA, USA; ^d Tampere University Hospital and Tampere University, Tampere, Finland; ^e Institute of Oncology, Vilnius University, Vilnius, Lithuania; ^f Department of Urology, Pauls Stradins Clinical University Hospital, Riga, Latvia; ^g Department of Urology, N. N. Alexandrov National Cancer Centre, Minsk, Belarus; ^h Department of Urology, Lithuanian University of Health Sciences, Medical Academy, Kaunas, Lithuania; ⁱ Hospital Erasto Gaertner, Curitiba, Brazil; ^j Hertsen Moscow Oncology Research Institute, Moscow, Russia; ^k Hopital Foch, Suresnes, France; ^l University Hospital Magdeburg, Magdeburg, Germany; ^m Bayer Consumer Care AG, Basel, Switzerland; ⁿ Bayer HealthCare, Loos, France; ^o Bayer HealthCare, Whippany, NJ, USA; ^p Orion Corporation Orion Pharma, Espoo, Finland; ^q Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France

Article info

Article history:
Accepted July 22, 2022

Associate Editor:
Maarten Albersen

Statistical Editor:
Rodney Dunn

Keywords:
Androgen receptor inhibitor
Darolutamide
Metastasis-free survival
Nonmetastatic castration-

Abstract

Background: Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) have a high risk of progression to metastatic disease, particularly if their prostate-specific antigen doubling time (PSADT) is ≤ 6 mo. However, patients remain at a high risk with a PSADT of >6 mo.

Objective: To evaluate the efficacy and safety of darolutamide versus placebo in patients stratified by PSADT >6 or ≤ 6 mo.

Design, setting, and participants: A planned subgroup analysis of a global multicenter, double-blind, randomized, phase 3 trial in men with nmCRPC and PSADT ≤ 10 mo was conducted.

Intervention: Patients were randomized 2:1 to oral darolutamide 600 mg twice daily or placebo, while continuing androgen-deprivation therapy.

Outcome measurements and statistical analysis: The primary endpoint was metastasis-free survival (MFS). Secondary endpoints were overall survival (OS) and times to pain progression, first cytotoxic chemotherapy, and symptomatic skeletal events. Quality of

* Corresponding author. Department of Urology, Münster University Medical Center, Albert-Schweitzer-Campus 1 GB A1, 48149 Münster, Germany. Tel.: +49 (0)2 51/83-44 60 0; Fax: +49 (0) 2 51/83-48 34 8.

E-mail address: martin.boegemann@ukmuenster.de (M. Bögemann).

resistant prostate cancer
Overall survival
Prostate-specific antigen
doubling time
Quality of life

life (QoL) was measured using validated prostate-relevant tools. Safety was recorded throughout the study.

Results and limitations: Of 1509 patients enrolled, 469 had PSADT >6 mo (darolutamide $n = 286$; placebo $n = 183$) and 1040 had PSADT ≤ 6 mo (darolutamide $n = 669$; placebo $n = 371$). Baseline characteristics were balanced between subgroups. Darolutamide significantly prolonged MFS versus placebo in both subgroups (unstratified hazard ratio [95% confidence interval]: PSADT >6 mo, 0.38 [0.26–0.55]; PSADT ≤ 6 mo, 0.41 [0.33–0.52]). OS and other efficacy and QoL endpoints favored darolutamide with significant improvement over placebo in both subgroups. The incidence of adverse events, including events commonly associated with androgen receptor inhibitors (fractures, falls, hypertension, and mental impairment), and discontinuations due to adverse events were low and similar to placebo. Limitations include small subgroup populations.

Conclusions: In patients with nmCRPC and PSADT >6 mo (maximum 10 mo), darolutamide provided a favorable benefit/risk ratio, characterized by significant improvements in MFS, OS, and other clinically relevant endpoints; maintenance of QoL; and favorable tolerability.

Patient summary: In patients with prostate cancer that has stopped responding to standard hormonal therapy (indicated by an increase in prostate-specific antigen [PSA] levels), there is a risk that the cancer will spread to other parts of the body. This risk is highest when the time it takes for the PSA level to double (ie, “PSA doubling time” [PSADT]) is less than 6 mo. However, there is still a risk that the cancer will spread even if the PSADT is longer than 6 mo. In a group of patients whose PSADT was more than 6 mo but no more than 10 mo, treatment with darolutamide slowed the cancer spread and allowed them to live longer than patients who received placebo (inactive drug). Darolutamide treatment did not cause many side effects and helped maintain patients’ quality of life without disruptions.

© 2022 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Nonmetastatic castration-resistant prostate cancer (nmCRPC) is diagnosed when a patient’s prostate-specific antigen (PSA) rises despite surgical or medical castration, without evidence of metastasis on conventional imaging [1]. Many patients have high risks of disease progression and development of metastatic disease [2]. Patients with nmCRPC are usually asymptomatic from their disease [1], although they often have adverse events from local treatment of the primary tumor and androgen-deprivation therapy (ADT), such as urinary and sexual dysfunction, hot flashes, and fatigue [3].

In the absence of clinically apparent signs of progressive disease, PSA level and rate of change, as quantified by PSA doubling time (PSADT), offer the best prognostic indicators of progression and survival outcome [4–9]. Any increase in PSA, no matter how small, warrants monitoring [8] because the window of opportunity to treat patients before progression to metastatic disease can be narrow [2]. There is evidence that a shorter PSADT indicates a higher risk of progression, which is associated with reduced survival [6,7,9,10]. Various thresholds have been proposed to distinguish between high and low risk of metastatic progression [11–15]; PSADT <6 mo is sometimes proposed as a cutoff to identify the need for more aggressive therapy [14,16,17]. However, international evidence-based guidelines recommend treatment with a new-generation androgen receptor inhibitor (ARI; ie, apalutamide, enzalutamide, or darolutamide) in addition to standard ADT when the PSADT is ≤ 10 mo [18,19].

Given the poorer prognosis in patients with metastatic disease and the fact that patients with nmCRPC are often asymptomatic from their cancer, the goals of treatment are to delay progression to metastatic disease and prolong survival, while minimizing treatment-related toxicity that can limit patients’ daily activities and health-related quality of life (HRQoL) [3,18,20–23]. Darolutamide is a structurally distinct ARI [21,22,24] that demonstrated significant improvements in metastasis-free survival (MFS) and overall survival (OS) versus placebo in patients with nmCRPC in the phase 3 ARAMIS trial [21,25]. The safety profile of darolutamide is consistently favorable, with $\leq 2\%$ difference versus placebo in the incidence of most ARI-associated adverse events and a low risk of central nervous system-related adverse events, likely due to its low blood–brain barrier penetration [21,22,24,26,27]. Darolutamide also has a low potential for drug–drug interactions (DDIs) with medications commonly used to treat comorbidities in patients with nmCRPC [28,29]. Minimizing the risks of adverse events and DDIs is an important component of optimal disease management in patients with nmCRPC, allowing them to maintain their QoL, while prolonging survival and delaying disease progression [23].

The pivotal phase 3 trial for darolutamide (ARAMIS) enrolled patients with PSADT ≤ 10 mo [21]. The aim of this preplanned ARAMIS subgroup analysis was to evaluate the efficacy and safety of darolutamide versus placebo in patients stratified by PSADT >6 versus ≤ 6 mo to help inform therapeutic decision-making, particularly in patients with PSADT 6–10 mo in whom there may be uncertainty about the benefit versus risk of treatment.

2. Patients and methods

ARAMIS was a global, multicenter, double-blind, randomized, phase 3 trial of darolutamide versus placebo plus ADT in men with nmCRPC (NCT02200614). The full methods have been reported previously [21,25] and are summarized briefly here.

2.1. Patients

The study enrolled men aged ≥ 18 yr with histologically or cytologically confirmed prostate adenocarcinoma, who had a PSA level of ≥ 2 ng/ml and a PSADT of ≤ 10 mo at screening and an Eastern Cooperative Oncology Group performance status of 0 or 1 at baseline. Patients with evidence of metastases or a history of metastatic disease on conventional bone scan, computed tomography, or magnetic resonance imaging were excluded. Patients with a previous seizure disorder or predisposition to seizure could be included.

2.2. Study design

Patients were randomized 2:1 to double-blind treatment with oral darolutamide 600 mg twice daily or matched placebo, while continuing ADT. Randomization was stratified by PSADT (>6 vs ≤ 6 mo) and use of osteoclast-targeted therapy (yes vs no). The PSADT for each patient was initially calculated locally during screening, but was recomputed centrally by the sponsor for this analysis to ensure consistency in the calculations. Treatment was continued until patients experienced protocol-defined progression or intolerable adverse events, commenced another anticancer treatment, or withdrew consent.

Unblinding occurred after the primary analysis, at which point patients initially randomized to darolutamide could continue open-label darolutamide, while those initially randomized to placebo could switch to open-label darolutamide or another treatment of the investigators' choice.

2.3. Study endpoints

The study had two planned analyses: the primary analysis was performed after 437 MFS events; the final analysis was performed after 254 OS events. The primary efficacy endpoint was MFS [21]. Secondary endpoints were OS, time to pain progression, time to initiation of first cytotoxic chemotherapy for prostate cancer, and time to first symptomatic skeletal event (SSE). Progression-free survival (PFS) was an exploratory efficacy endpoint.

Throughout the study, HRQoL was measured using the Functional Assessment of Cancer Therapy–Prostate (FACT-P) total and prostate cancer subscale scores (higher scores indicate better HRQoL), European Organisation for Research and Treatment of Cancer Quality of Life–Prostate cancer questionnaire (EORTC-QLQ-PR25) urinary symptom subscale scores (a higher score indicates a greater impact of symptoms on HRQoL), and Brief Pain Inventory–Short Form (BPI-SF) questionnaire scores for pain interference (higher scores indicate greater impact of pain) and pain severity (higher scores indicate greater pain).

Safety was assessed throughout the study. The incidence of treatment-emergent adverse events (TEAEs) was recorded, with the event type coded according to the Medical Dictionary for Regulatory Activities version 21.0 and severity graded using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03.

In this planned subgroup analysis, we report findings separately in patients with PSADT >6 or ≤ 6 mo.

2.4. Statistical analyses

Full details of the statistical analyses were published previously and are available in the statistical analysis plan at clinicaltrials.gov/ProvidedDocs/14/NCT02200614/SAP_001.pdf.

The efficacy and HRQoL analyses were based on the intention-to-treat (ITT) population, defined as all randomized patients, grouped according to treatment allocation. Missing event occurrence dates were imputed as the earliest possible dates. HRQoL analyses excluded patients with missing baseline data. Safety analyses were based on the safety population, defined as all randomized patients who received one or more doses of study medication, grouped according to the treatment actually received.

Statistical analyses were performed using SAS software, version 9.2 (SAS Institute, Cary, NC, USA). Time-to-event endpoints were estimated using the Kaplan–Meier method, and were reported as medians with range and 95% confidence intervals (CIs). Hazard ratios (HRs) and 95% CIs, based on Cox regression modeling and log-rank testing without stratification, were reported for comparisons between the darolutamide and placebo treatment arms within each PSADT subgroup and for a univariate analysis of MFS by baseline age, race, and region. For HRQoL measures, differences between treatment arms were reported as least squares mean (LSM) differences in time-adjusted area under the curve (AUC) using analysis of covariance. Changes in HRQoL measures over time were reported descriptively.

2.5. Study ethics

The study protocol was approved by the institutional review board at each participating center. The study was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonisation guidelines for Good Clinical Practice. All patients provided written informed consent for participation. Unblinded safety data were reviewed by an independent data and safety monitoring board.

3. Results

3.1. Patients

The data cutoff dates for the primary and final analyses were September 3, 2018 [21], and November 15, 2019 [25], respectively. The median follow-up duration for OS was 29 mo. The overall ITT population comprised 1509 patients (darolutamide $n = 955$; placebo $n = 554$), of whom 469 had a PSADT of >6 – ≤ 10 mo (darolutamide $n = 286$; placebo $n = 183$) and 1040 had a PSADT of ≤ 6 mo (darolutamide $n = 669$; placebo $n = 371$).

Baseline characteristics were generally well balanced between the PSADT subgroups (Table 1), although the median time from the initial diagnosis was longer in the PSADT >6 mo subgroup (darolutamide arm 97 mo; placebo arm 95 mo) than in the PSADT ≤ 6 mo subgroup (darolutamide arm 82 mo; placebo arm 79 mo). The proportions of patients with prior local therapy were generally similar between treatment arms in both subgroups. In the PSADT >6 mo subgroup, 19% of patients who received darolutamide and 18% of patients who received placebo had previously undergone prostatectomy; in the PSADT ≤ 6 mo subgroup, the proportions were 28% and 27%, respectively. For prior radiotherapy, the proportions were 18% and 13%, respectively, in

Table 1 – Patient demographics and clinical characteristics at baseline

Baseline characteristic ^a	PSADT >6 mo		PSADT ≤6 mo	
	Darolutamide (n = 286 ^b)	Placebo (n = 183)	Darolutamide (n = 669)	Placebo (n = 371)
Age (yr), median (IQR)	76 (70–81)	75 (70–80)	74 (68–79)	72 (67–79)
Age (yr), n (%)				
<65	31 (11)	20 (11)	82 (12)	64 (17)
65–74	94 (33)	61 (33)	279 (42)	155 (42)
75–84	134 (47)	81 (44)	250 (37)	128 (35)
≥85	27 (9)	21 (11)	58 (9)	24 (7)
ECOG performance status, n (%)				
0	187 (65)	126 (69)	463 (69)	265 (71)
1	99 (35)	57 (31)	206 (31)	106 (29)
Gleason score at initial diagnosis, n (%)				
<7	69 (24)	48 (26)	148 (22)	94 (25)
≥7	208 (73)	127 (69)	503 (75)	268 (72)
Time from initial diagnosis (mo), median (IQR)	97 (62–129)	95 (57–147)	82 (47–126)	79 (44–130)
Primary tumor classification, n (%)				
T2: tumor confined within the prostate	30 (10)	16 (9)	80 (12)	42 (11)
T3a: unilateral or bilateral extracapsular extension	25 (9)	19 (10)	88 (13)	30 (8)
Pathological lymph nodes on central imaging review, n (%)	23 (8)	14 (8)	77 (12)	52 (14)
Serum PSA (ng/ml), median (IQR)	8.9 (4.4–18)	9.3 (4.7–19)	9.2 (4.5–21)	10 (5.1–22)
PSADT (mo), median (IQR) ^c	7.8 (6.9–9.0)	7.3 (6.6–8.2)	3.5 (2.5–4.6)	3.6 (2.5–4.7)
Serum testosterone (nmol/l), median (IQR)	0.54 (0.46–0.71)	0.54 (0.44–0.69)	0.56 (0.47–0.71)	0.56 (0.47–0.75)
Prior hormonal therapy, n (%)				
1	58 (20)	30 (16)	119 (18)	73 (20)
≥2	209 (73)	139 (76)	518 (77)	281 (76)
NA	19 (7)	14 (8)	32 (5)	17 (5)
Prior local therapy, n (%)				
Prostatectomy	53 (19)	33 (18)	186 (28)	101 (27)
Radiotherapy	51 (18)	23 (13)	126 (19)	66 (18)

ECOG = Eastern Cooperative Oncology Group; IQR = interquartile range; NA = not applicable; PSA = prostate-specific antigen; PSADT = prostate-specific antigen doubling time.

^a Data are missing for some patients and categories.

^b In the initial ARAMIS report [21], 288 patients had PSADT >6 mo based on local calculations at screening. PSADT was recomputed centrally by the sponsor for this analysis to ensure consistency in the calculations, resulting in some discrepancies versus the values recorded during screening.

^c Although patients had to have a PSADT of ≤10 mo at screening, as calculated locally by the investigator, recalculation of all PSADTs centrally by the sponsor and changes in PSADT between screening and the start of treatment resulted in some patients having a PSADT of >10 mo at baseline.

the PSADT >6 mo subgroup and 19% and 18%, respectively, in the PSADT ≤6 mo subgroup.

3.2. Efficacy

At the primary analysis, darolutamide significantly reduced the risk of metastasis or death versus placebo by 62% in the PSADT >6 mo subgroup (unstratified HR 0.38, 95% CI 0.26–0.55) and by 59% in the PSADT ≤6 mo subgroup (unstratified HR 0.41, 95% CI 0.33–0.52; Fig. 1). The MFS benefit with darolutamide versus placebo was consistent across PSADT quartiles, with HRs ranging from 0.33 to 0.48 (Supplementary Table 1). When evaluating MFS by baseline characteristics, the results were generally consistently in favor of darolutamide over placebo, regardless of age, race, or region, although 95% CIs were wide, and crossed 1 for age 74–79 yr (n = 140), age 47–67 yr (n = 81), non-White race (n = 82), and Asia-Pacific region (n = 43) in the PSADT >6 mo subgroup (Fig. 2).

At the final analysis, darolutamide significantly prolonged OS versus placebo in both PSADT subgroups (Fig. 1). The risk of death was reduced by 45% in the PSADT >6 mo subgroup (p = 0.01) and by 26% in the PSADT ≤6 mo subgroup (p = 0.04) with darolutamide versus placebo. The OS benefit of darolutamide over placebo was consistent across PSADT quartiles, although CIs were wide and often overlapping 1 (Supplementary Table 2).

The benefit of darolutamide over placebo was seen in both PSADT subgroups for all other efficacy endpoints

(Fig. 3). For time to pain progression and PFS, significant differences were achieved at the primary analysis in both subgroups. For time to first cytotoxic chemotherapy and time to first SSE, significant differences were achieved at the final analysis, except for the time to first SSE in the PSADT >6 mo subgroup (p = 0.06).

3.3. Health-related quality of life

HRQoL was maintained with darolutamide versus placebo in both subgroups (Supplementary Fig. 1 and Supplementary Table 3). For all HRQoL subscale measures, LSM differences in time-adjusted AUC showed a positive trend for darolutamide versus placebo, although these did not meet the minimally important differences required to be clinically meaningful.

3.4. Safety and tolerability

The median duration of study drug administration was generally consistent between subgroups. In patients randomized to darolutamide, the median duration of darolutamide treatment was 18 mo in the PSADT >6 mo subgroup versus 19 mo in the PSADT ≤6 mo subgroup during the double-blind period, and 26 mo in each subgroup across the double-blind and open-label periods. In patients randomized to placebo, the median duration of study treatment was 15 mo (PSADT >6 mo subgroup) versus 11 mo (PSADT ≤6 mo subgroup) for placebo during the double-




Fig. 1 – Darolutamide efficacy by PSADT subgroup. Kaplan–Meier estimates of metastasis-free survival (primary analysis): (A) PSADT >6 mo subgroup and (B) PSADT ≤6 mo subgroup; and overall survival (final analysis): (C) PSADT >6 mo subgroup and (D) PSADT ≤6 mo subgroup. HRs and 95% CIs were based on a Cox regression model, without stratification. CI = confidence interval; HR = hazard ratio; MFS = metastasis-free survival; NR = not reached; OS = overall survival; PSADT = prostate-specific antigen doubling time.




Fig. 2 – Metastasis-free survival analyses by baseline characteristics. Nominal 95% CIs are provided without controlling for multiple inferences. CI = confidence interval; HR = hazard ratio; PSADT = prostate-specific antigen doubling time.




Fig. 3 – Secondary and exploratory endpoint outcomes during double-blind treatment by PSADT subgroup: >6 mo (left-hand column) and ≤6 mo (right-hand column): (A) Time to pain progression^a, (B) time to initiation of first cytotoxic chemotherapy, (C) time to first symptomatic skeletal event, and (D) progression-free survival^a. Nominal inferential statistics are presented without controlling for multiple inferential analyses. CI = confidence interval; NR = not reached; PSADT = prostate-specific antigen doubling time. ^aPrimary analysis.

Table 2 – TEAEs of interest in the safety population during the double-blind period^a

TEAE	PSADT >6 mo						PSADT ≤6 mo					
	Darolutamide (n = 286)			Placebo (n = 183)			Darolutamide (n = 668)			Placebo (n = 371)		
	Any grade, n (%)	Grade 3/4, n (%) ^b	EAIR ^c	Any grade, n (%)	Grade 3/4, n (%) ^b	EAIR ^c	Any grade, n (%)	Grade 3/4, n (%) ^b	EAIR ^c	Any grade, n (%)	Grade 3/4, n (%) ^b	EAIR ^c
Fatigue	42 (15)	1 (0.35)	9.0	19 (10)	2 (1.1)	8.1	84 (13)	3 (0.45)	8.0	27 (7.3)	3 (0.81)	6.9
Bone fracture ^d	16 (5.6)	2 (0.70)	3.4	12 (6.6)	5 (2.7)	5.1	36 (5.4)	8 (1.2)	3.4	8 (2.2)	0	2.1
Falls (including accidents)	17 (5.9)	2 (0.70)	3.6	12 (6.6)	2 (1.1)	5.1	33 (4.9)	7 (1.0)	3.1	15 (4.0)	2 (0.54)	3.9
Weight decreased	13 (4.5)	0	2.8	7 (3.8)	0	3.0	27 (4.0)	0	2.6	7 (1.9)	0	1.8
Asthenic conditions ^e	13 (4.5)	0	2.8	8 (4.4)	1 (0.5)	3.4	29 (4.3)	2 (0.30)	2.8	15 (4.0)	2 (0.54)	3.9
Rash ^f	8 (2.8)	0	1.7	1 (0.55)	0	0.4	22 (3.3)	2 (0.30)	2.1	5 (1.3)	0	1.3
Mental impairment disorders ^g	5 (1.7)	0	1.1	5 (2.7)	0	2.1	14 (2.1)	3 (0.45)	1.3	5 (1.3)	0	1.3
Depressed mood disorders ^g	5 (1.7)	1 (0.35)	1.1	3 (1.6)	0	1.3	16 (2.4)	0	1.5	7 (1.9)	0	1.8
Hypertension	18 (6.3)	5 (1.7)	3.8	13 (7.1)	5 (2.7)	5.5	56 (8.4)	28 (4.2)	5.3	23 (6.2)	8 (2.2)	5.9
Hot flush ^h	17 (5.9)	0	3.6	8 (4.4)	0	3.4	40 (6.0)	0	3.8	17 (4.6)	0	4.4
Cardiac arrhythmia ^g	24 (8.4)	3 (1.0)	5.1	11 (6.0)	2 (1.1)	4.7	46 (6.9)	14 (2.1)	4.4	13 (3.5)	2 (0.54)	3.3
Coronary artery disorders ^g	14 (4.9)	8 (2.8)	3.0	5 (2.7)	2 (1.1)	2.1	24 (3.6)	11 (1.6)	2.3	10 (2.7)	0	2.6
Heart failure ^g	3 (1.0)	1 (0.35)	0.6	3 (1.6)	0	1.3	15 (2.2)	3 (0.45)	1.4	2 (0.54)	0	0.5

EAIR = exposure-adjusted incidence rate; MedDRA = Medical Dictionary for Regulatory Activities; PSADT = prostate-specific antigen doubling time; TEAE = treatment-emergent adverse event.

^a TEAEs of interest commonly associated with androgen receptor inhibitors.

^b EAIR is for any-grade TEAE per 100 patient-years.

^c The following grade 5 TEAEs were recorded: cardiac arrhythmia (PSADT >6 mo subgroup: darolutamide n = 1 [0.35%], placebo n = 2 [1.1%]; PSADT ≤6 mo subgroup: darolutamide n = 1 [0.15%], placebo n = 1 [0.27%]), coronary artery disorders (PSADT >6 mo subgroup: darolutamide n = 2 [0.70%], placebo n = 0; PSADT ≤6 mo subgroup: darolutamide n = 1 [0.15%], placebo n = 1 [0.27%]), and heart failure (PSADT >6 mo subgroup: darolutamide n = 0; placebo n = 2 [1.1%]; PSADT ≤6 mo subgroup: darolutamide n = 5 [0.75%], placebo n = 1 [0.27%]).

^d This category combines the following MedDRA version 22.1 terms: any fractures and dislocations; limb fractures and dislocations; pelvic fractures and dislocations; skull fractures, facial bone fractures, and dislocations; spinal fractures and dislocations; and thoracic cage fractures and dislocations.

^e This category combines the following MedDRA terms: asthenic conditions, disturbances in consciousness, decreased strength and energy, malaise, lethargy, and asthenia.

^f This category combines the following MedDRA terms: rash, macular rash, maculopapular rash, papular rash, and pustular rash.

^g This category is a MedDRA high-level group term.

^h This category combines the following MedDRA terms: flushing, hot flush, and vasodilatation.

blind period and 11 mo in each subgroup for darolutamide during the open-label period.

The safety profile of darolutamide was consistent between the PSADT subgroups, with a low incidence of grade 3–4 events and discontinuations due to TEAEs in both subgroups (Table 2 and Supplementary Table 4). During double-blind treatment, most TEAEs commonly associated with ARIs (including fractures, falls, hypertension, and mental impairment disorders) showed a difference of $\leq 3\%$ between darolutamide and placebo in both subgroups; fatigue was the only adverse event with an incidence of $>10\%$ in the darolutamide arm (15% in the PSADT >6 mo subgroup and 13% in the PSADT ≤ 6 mo subgroup vs 10% and 7.3%, respectively, in the placebo arm; Table 2); most fatigue events were of grade 1 (PSADT >6 mo subgroup: darolutamide 8.7% and placebo 7.7%; PSADT ≤ 6 mo subgroup: darolutamide 9.1% and placebo 5.4%). When adjusted for exposure, differences in the incidence of these TEAEs of interest between darolutamide and placebo were minimal in both subgroups. The incidence of TEAEs that occurred in $\geq 5\%$ of patients in either treatment group was generally similar in both subgroups, with the most frequently reported TEAEs in either subgroup being fatigue, back pain, and arthralgia (Supplementary Table 4). In both subgroups, the types of TEAEs reported in patients who crossed over from placebo to darolutamide during the open-label period were consistent with those observed with darolutamide treatment during the double-blind period (Supplementary Table 4).

4. Discussion

In patients with nmCRPC, PSADT is a prognostic factor for progression to metastatic disease, with a shorter PSADT indicating a higher risk of progression [9]. This preplanned subgroup analysis of ARAMIS demonstrated that patients with PSADT >6 mo benefited from darolutamide treatment to a similar extent to those with PSADT ≤ 6 mo, with significant improvements in MFS and OS, as well as favorable trends in other efficacy endpoints and HRQoL. Age, race, and region had no impact on MFS outcomes, with consistent benefits in favor of darolutamide over placebo, although some 95% CIs in the PSADT >6 mo subgroup were wide and crossed 1, reflecting the small sample sizes. Most darolutamide-induced improvements in HRQoL were smaller than the minimally important differences for the scales employed; however, the overall trends toward improvement of patient-reported outcome measures of HRQoL were encouraging. Darolutamide was well tolerated, and the safety profile was similar across the two PSADT subgroups and comparable to that of the overall population. The incidence of most TEAEs was consistently low and similar to the placebo arm, indicating that treatment with darolutamide may have minimal negative impact on patients' HRQoL.

The ARAMIS study was restricted to patients with PSADT ≤ 10 mo, which is the accepted cutoff to define a high risk of progression and early mortality in patients with nmCRPC [6,7,18]. The association between rapid PSADT and poor prognosis is widely recognized [4,5,9,30–37], and PSADT ≤ 6 mo indicates the highest risk of progression to meta-

static disease [9,30]. However, the potentially negative impact of drug-induced adverse events on HRQoL is an important consideration in men with nmCRPC and PSADT >6 mo, given the anticipated long treatment duration; the risk of experiencing adverse events is especially higher in elderly men with comorbidities. We show that in patients with PSADT >6 – ≤ 10 mo, darolutamide offers significant MFS and OS benefits, as well as improvement in other patient-relevant endpoints, without imposing undue toxicity burden or adversely affecting HRQoL. In the pivotal phase 3 studies of other ARIs, findings from PSADT subgroup analyses were less clear. A subgroup analysis of PROSPER using a PSADT cutoff of ≥ 6 versus <6 mo indicated MFS benefits with enzalutamide versus placebo in both PSADT subgroups, whereas for OS, the 95% CI crossed 1 in the PSADT ≥ 6 mo subgroup [6,38]. In a subgroup analysis of SPARTAN using a PSADT cutoff of >6 versus ≤ 6 mo, apalutamide showed MFS benefits versus placebo in both PSADT subgroups; for OS, the 95% CI crossed 1 in the PSADT ≤ 6 mo subgroup [7,39].

As a subgroup analysis, the statistical power is reduced due to the smaller patient populations in each treatment arm within each subgroup compared with the overall population. Nonetheless, because PSADT was a stratification factor for randomization, the groups were well balanced, minimizing the selection bias. Furthermore, we cannot rule out that patients might have had evidence of metastases on newer imaging modalities, such as prostate-specific membrane antigen positron-emission tomography/computed tomography or whole-body diffusion-weighted magnetic resonance imaging. All patients, however, met the entry criterion of nmCRPC on conventional imaging, and the balanced baseline characteristics between treatment arms suggest that the findings apply regardless of metastases that were not evident on conventional imaging. ARAMIS was restricted to patients with a PSADT of ≤ 10 mo; therefore, conclusions from the PSADT >6 mo subgroup should not be extrapolated to patients with nmCRPC and a PSADT of >10 mo. Finally, the low reported rate of prior local therapy, which is similar to other reported large datasets [40], might be a potential limitation, but reflects the patient population enrolled in this trial.

5. Conclusions

In conclusion, in patients with nmCRPC and a PSADT of >6 mo, darolutamide provided a markedly favorable benefit-to-risk ratio, characterized by significant improvement in survival and other clinically relevant endpoints; maintained HRQoL; and demonstrated a favorable tolerability profile. Thus, early initiation of life-prolonging therapy with an ARI is warranted in these patients.

Author contributions: Martin Bögemann had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Shore, Smith, Verholen, Le Berre, Ortiz, Mohamed, Fizazi.

Acquisition of data: Bögemann, Shore, Smith, Tammela, Ulys, Vjaters, Polyakov, Jievaltas, Luz, Alekseev, Lebret, Schostak, Fizazi.

Analysis and interpretation of data: Verholen, Le Berre, Srinivasan, Ortiz, Mohamed.

Drafting of the manuscript: Bögemann, Shore, Smith, Tammela, Ulys, Vjaters, Polyakov, Jievaltas, Luz, Alekseev, Lebret, Schostak, Verholen, Le Berre, Srinivasan, Ortiz, Mohamed, Sarapohja, Fizazi.

Critical revision of the manuscript for important intellectual content: Bögemann, Shore, Smith, Tammela, Ulys, Vjaters, Polyakov, Jievaltas, Luz, Alekseev, Lebret, Schostak, Verholen, Le Berre, Srinivasan, Ortiz, Mohamed, Sarapohja, Fizazi.

Statistical analysis: Le Berre, Srinivasan.

Obtaining funding: None.

Administrative, technical, or material support: None.

Supervision: None.

Other: None.

Financial disclosures: Martin Bögemann certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Martin Bögemann—advisory role and honoraria: Amgen, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb (BMS), Eisai, Janssen, EUSA Pharma, Ipsen, Lilly, Merck, Merck Sharp & Dohme (MSD), Novartis, Pfizer, and Sanofi; his institution has received research grants from Astellas and Janssen. Neal D. Shore—consulting or advisory role and speaker's bureau: Bayer, Janssen Scientific Affairs, Dendreon, Tolmar, Ferring, Medivation/Astellas, Amgen, Pfizer, AstraZeneca, Myovant Sciences, Astellas Pharma, AbbVie, Merck, BMS/Sanofi, Boston Scientific, Clovis Oncology, Exact Imaging, FerGene, Foundation Medicine, CG Oncology, InVitae, MDxHealth, Myriad Genetics, Nymox, Propella Therapeutics, Genzyme, Sanofi, and Sesen Bio; grant or research support: AbbVie, Amgen, Astellas Pharma, AstraZeneca, Bayer, BMS/Pfizer, Boston Scientific, Clovis Oncology, Dendreon, Exact Imaging, Ferring, Foundation Medicine, InVitae, Janssen, MDxHealth, Merck, Myovant Sciences, Myriad Genetics, Nymox, Pfizer, Sanofi, Sesen Bio, and Tolmar; employment: GenesisCare, USA. Matthew R. Smith—consulting or advisory role: Amgen, Astellas Pharma, Bayer, Janssen Oncology, Lilly, Novartis, and Pfizer; travel, accommodation, and expenses: Amgen, Bayer, Janssen, and Lilly; research funding to institution: Bayer, ESSA, Janssen Oncology, Lilly, and ORIC Pharmaceuticals. Teuvo L.J. Tammela—consulting: Astellas, Bayer, Janssen, and Orion Pharma. Albertas Ulys—nothing to disclose. Egils Vjaters—consulting or advisory role: Bayer, Janssen, and Orion Pharma. Sergey Polyakov—research grant: Ministry of Health Belarus; honorarium: Ferring; travel support: Astellas and Pfizer; leadership role: Belarusian Society of Oncologists. Mindaugas Jievaltas—consulting: Astellas and Janssen; honoraria: Astellas, Ipsen, and Janssen; expert testimony: Astellas; travel, accommodation, and expenses: Bayer, Ipsen, and Janssen. Murilo Luz—speaker's bureau: Astellas, Bayer, Janssen, and Sanofi; research grant: Amgen, AstraZeneca, Ferring, and ProScan; sponsored research: Active Biotech, Bayer, Ferring, GSK, and Janssen; advisory board: Astellas, Janssen, and ProScan; travel support: AstraZeneca, Bayer, Janssen, and Pfizer. Boris Alekseev—research funding, consulting, and speakers' bureau: Astellas, AstraZeneca, Bayer, Bliss, MSD, Roche, and Sanofi; research funding: Janssen. Thierry Lebret—nothing to disclose. Martin Schostak—consulting or advisory role: AstraZeneca, Bayer, BMS, and MSD; honoraria: AstraZeneca, Bayer, BMS, and MSD. Frank Verholen, Marie-Aude Le Berre, Shankar Srinivasan, Jorge Ortiz, Ateesha F. Mohamed—employees of Bayer. Toni Sarapohja—employee of Orion Pharma. Karim Fizazi—advisory role, talks, and honoraria: (to institution—Gustave Roussy) Amgen, Astellas, AstraZeneca, Bayer, Clovis, Jans-

sen, MSD, Novartis/Advanced Accelerator Applications, and Sanofi; advisory role and honoraria (personal): CureVac and Orion.

Funding/support and role of the sponsor: This trial was supported by Orion Corporation, Orion Pharma, and Bayer AG. The sponsors were involved in trial design, data collection and analysis, data reporting, and development of this manuscript.

Data sharing: Availability of the data underlying this publication will be determined later according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, time point, and process of data access. As such, Bayer commits to sharing, upon request from qualified scientific and medical researchers, patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the USA and European Union (EU), as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 1, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct further research that can help advance medical science or improve patient care. Information on the Bayer criteria for listing studies and other relevant information are provided in the study sponsors' section of the portal. Data access will be granted to anonymized patient-level data, protocols, and clinical study reports after approval by an independent scientific review panel. Bayer is not involved in the decisions made by the independent review panel. Bayer will take all necessary measures to ensure that patient privacy is safeguarded.

Acknowledgments: Writing and editorial support in the development of this manuscript was provided by Sara Black, ISMPP CMPP, and Lauren Gallagher, RPh, PhD, of OPEN Health Communications, London, UK, with financial support from Bayer Healthcare. The authors retained full editorial control over the content of the manuscript and the decision to publish.

Peer Review Summary

Peer Review Summary and Supplementary data to this article can be found online at <https://doi.org/10.1016/j.eururo.2022.07.018>.

References

- [1] Saad F, Bögemann M, Suzuki K, Shore N. Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors. *Prostate Cancer Prostatic Dis* 2021;24:323–34.
- [2] Lavaud P, Dumont C, Thibault C, et al. Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer. *Ther Adv Med Oncol* 2020;12, 1758835920978134.
- [3] Tomaszewski EL, Moise P, Krupnick RN, et al. Symptoms and impacts in non-metastatic castration-resistant prostate cancer: qualitative study findings. *Patient* 2017;10:567–78.
- [4] Smith MR, Kabbavar F, Saad F, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. *J Clin Oncol* 2005;23:2918–25.
- [5] Smith MR, Cook R, Lee KA, Nelson JB. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. *Cancer* 2011;117:2077–85.

- [6] Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. *N Engl J Med* 2018;378:2465–74.
- [7] Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. *N Engl J Med* 2018;378:1408–18.
- [8] Saad F, Sternberg CN, Efstathiou E, et al. Prostate-specific antigen progression in enzalutamide-treated men with nonmetastatic castration-resistant prostate cancer: any rise in prostate-specific antigen may require closer monitoring. *Eur Urol* 2020;78:847–53.
- [9] Smith MR, Saad F, Oudard S, et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. *J Clin Oncol* 2013;31:3800–6.
- [10] Nguyen T, Boldt RG, Rodrigues G. Prognostic factors for prostate cancer endpoints following biochemical failure: a review of the literature. *Cureus* 2015;7:e238.
- [11] D'Amico AV, Hanks GE. Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. *Cancer* 1993;72:2638–43.
- [12] Antonarakis ES, Chen Y, Elsamnoudi SI, et al. Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database. *BJU Int* 2011;108:378–85.
- [13] Markowski MC, Chen Y, Feng Z, et al. PSA doubling time and absolute PSA predict metastasis-free survival in men with biochemically recurrent prostate cancer after radical prostatectomy. *Clin Genitourin Cancer* 2019;17:470–475.e1.
- [14] Caffo O, Maines F, Kinspergher S, Vecchia A, Messina C. To treat or not to treat: is it acceptable to avoid active therapies in advanced prostate cancer today? *Expert Rev Anticancer Ther* 2021;21:389–400.
- [15] Campbell SR, Tom MC, Agrawal S, et al. Integrating prostate-specific antigen kinetics into contemporary predictive nomograms of salvage radiotherapy after radical prostatectomy. *Eur Urol Oncol* 2022;5:304–13.
- [16] National Institute for Health and Care Excellence. Enzalutamide for hormone-relapsed non-metastatic prostate cancer. Technology appraisal guidance TA580. www.nice.org.uk/guidance/ta580.
- [17] Agencia Española de Medicamentos y Productos Sanitarios. Informe de Posicionamiento Terapéutico de darolutamida (Nubeqa®) en cáncer de próstata resistente a la castración no metastásico. <https://www.aemps.gob.es/informa/informes-de-posicionamiento-terapeutico/informe-de-posicionamiento-terapeutico-de-darolutamida-nubeqa-en-cancer-de-prostata-resistente-a-la-castracion-no-metastasio/>.
- [18] Mottet N, Cornford P, van den Bergh RCN, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer 2021. <https://uroweb.org/guideline/prostate-cancer/>.
- [19] Lowrance W, Breau R, Chou R, et al. Advanced prostate cancer: AUA/ASTRO/SUO guideline. <https://www.auanet.org/documents/Guidelines/PDF/Advanced%20Prostate%20Cancer%20Guideline.pdf>.
- [20] Mateo J, Fizazi K, Gillessen S, et al. Managing nonmetastatic castration-resistant prostate cancer. *Eur Urol* 2019;75:285–93.
- [21] Fizazi K, Shore N, Tammela TL, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. *N Engl J Med* 2019;380:1235–46.
- [22] Fizazi K, Smith MR, Tombal B. Clinical development of darolutamide: a novel androgen receptor antagonist for the treatment of prostate cancer. *Clin Genitourin Cancer* 2018;16:332–40.
- [23] Smith MR, Shore N, Tammela TL, et al. Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the phase III ARAMIS trial. *Eur J Cancer* 2021;154:138–46.
- [24] Moilanen AM, Riikonen R, Oksala R, et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. *Sci Rep* 2015;5:12007.
- [25] Fizazi K, Shore N, Tammela TL, et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. *N Engl J Med* 2020;383:1040–9.
- [26] Zurth C, Sandman S, Trummel D, Seidel D, Nubbemeyer R, Gieschen H. Higher blood-brain barrier penetration of [14C]apalutamide and [14C]enzalutamide compared to [14C]darolutamide in rats using whole-body autoradiography. *J Clin Oncol* 2019;37:156.
- [27] Williams S, Mazibuko N, O'Daly O, et al. Significant localized reduction in cerebral blood flow (CBF) in regions relevant to cognitive function with enzalutamide (ENZA) compared to darolutamide (DARO) and placebo (PBO) in healthy volunteers. *J Clin Oncol* 2020;38:326.
- [28] Shore N, Zurth C, Fricke R, et al. Evaluation of clinically relevant drug-drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: results of pre-specified and post hoc analyses of the phase III ARAMIS trial. *Target Oncol* 2019;14:527–39.
- [29] Zurth C, Koskinen M, Fricke R, et al. Drug-drug interaction potential of darolutamide: in vitro and clinical studies. *Eur J Drug Metab Pharmacokinet* 2019;44:747–59.
- [30] Nguyen-Nielsen M, Liede A, Maegbaek ML, et al. Survival and PSA-markers for mortality and metastasis in nonmetastatic prostate cancer treated with androgen deprivation therapy. *Cancer Epidemiol* 2015;39:623–32.
- [31] Moreira DM, Howard LE, Sourbeer KN, et al. Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer. *Prostate Cancer Prostatic Dis* 2015;18:333–7.
- [32] Moreira DM, Howard LE, Sourbeer KN, et al. Predictors of time to metastasis in castration-resistant prostate cancer. *Urology* 2016;96:171–6.
- [33] Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. *J Clin Oncol* 2016;34:1402–18.
- [34] Howard LE, Moreira DM, De Hoedt A, et al. Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer. *BJU Int* 2017;120:e80–6.
- [35] Aly M, Hashim M, Heeg B, et al. Time-to-event outcomes in men with nonmetastatic castrate-resistant prostate cancer—a systematic literature review and pooling of individual participant data. *Eur Urol Focus* 2019;5:788–98.
- [36] Whitney CA, Howard LE, Freedland SJ, et al. Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer. *Prostate Cancer Prostatic Dis* 2019;22:252–60.
- [37] Freedland SJ, Pilon D, Bhak RH, Lefebvre P, Li S, Young-Xu Y. Predictors of survival, healthcare resource utilization, and healthcare costs in veterans with non-metastatic castration-resistant prostate cancer. *Urol Oncol* 2020;38:930.e13–e21.
- [38] Sternberg CN, Fizazi K, Saad F, et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. *N Engl J Med* 2020;382:2197–206.
- [39] Smith MR, Saad F, Chowdhury S, et al. Apalutamide and overall survival in prostate cancer. *Eur Urol* 2021;79:150–8.
- [40] De Giorgi U, Efstathiou E, Berry WR, et al. A phase III, randomized, double-blind, placebo-controlled study of enzalutamide in men with nonmetastatic castration-resistant prostate cancer: post-hoc analysis of PROSPER by prior therapy. *J Clin Oncol* 2019;37 (Suppl):185.